# A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

> **NCT02779751** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Breast Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Pembrolizumab
- **DRUG:** Anastrozole

## Key facts

- **NCT ID:** NCT02779751
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-14
- **Primary completion:** 2020-02-03
- **Final completion:** 2026-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02779751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02779751, "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02779751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*